These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
301 related items for PubMed ID: 6812366
21. Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia. Hyman CB, Agness CL, Rodriguez-Funes R, Zednikova M. Ann N Y Acad Sci; 1985; 445():293-303. PubMed ID: 3860133 [Abstract] [Full Text] [Related]
22. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998 [No Abstract] [Full Text] [Related]
23. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol. Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ. Hemoglobin; 2009 Dec; 33(5):312-22. PubMed ID: 19814677 [Abstract] [Full Text] [Related]
24. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography. Flynn DM, Hoffbrand AV, Politis D. Birth Defects Orig Artic Ser; 1982 Dec; 18(7):347-53. PubMed ID: 6819017 [No Abstract] [Full Text] [Related]
25. Combined therapy with desferrioxamine and deferiprone: a new protocol for iron chelation in thalassemia. D'Angelo E, Mirra N, Rocca A, Carnelli V. J Pediatr Hematol Oncol; 2004 Jul; 26(7):451-3. PubMed ID: 15218422 [Abstract] [Full Text] [Related]
26. Combined oral and parenteral iron chelation in beta thalassaemia major. Balveer K, Pyar K, Wonke B. Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163 [Abstract] [Full Text] [Related]
27. Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience. Calleja EM, Shen JY, Lesser M, Grady RW, New MI, Giardina PJ. Ann N Y Acad Sci; 1998 Jun 30; 850():469-70. PubMed ID: 9668587 [No Abstract] [Full Text] [Related]
28. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Hemoglobin; 2008 Jun 30; 32(1-2):41-7. PubMed ID: 18274982 [Abstract] [Full Text] [Related]
29. Objectives and mechanism of iron chelation therapy. Hershko C, Link G, Konijn AM, Cabantchik ZI. Ann N Y Acad Sci; 2005 Jun 30; 1054():124-35. PubMed ID: 16339658 [Abstract] [Full Text] [Related]
30. Response to long-term deferoxamine therapy in thalassemia. Cohen A, Martin M, Schwartz E. J Pediatr; 1981 Nov 30; 99(5):689-94. PubMed ID: 7299539 [Abstract] [Full Text] [Related]
31. [Intensive intravenous chelation in thalassemic patients with iron overload]. Di Gregorio F, Leonardi C, Sciuto C, Cannella A, Pizzarelli G. Minerva Pediatr; 1998 Mar 30; 50(3):81-5. PubMed ID: 9676102 [Abstract] [Full Text] [Related]
32. Iron metabolism in thalassemia intermedia. Fiorelli G, Fargion S, Piperno A, Battafarano N, Cappellini MD. Haematologica; 1990 Mar 30; 75 Suppl 5():89-95. PubMed ID: 2086386 [Abstract] [Full Text] [Related]
33. Treatment of iron overload in Cooley's anemia. Cohen A, Mizanin J, Schwartz E. Ann N Y Acad Sci; 1985 Mar 30; 445():274-81. PubMed ID: 3860130 [No Abstract] [Full Text] [Related]
34. Cooley anemia: high transfusion regimen and chelation therapy, results, and perspective. Weiner M, Karpatkin M, Hart D, Seaman C, Vora SK, Henry WL, Piomelli S. J Pediatr; 1978 Apr 30; 92(4):653-8. PubMed ID: 633033 [No Abstract] [Full Text] [Related]
35. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Cossu P, Toccafondi C, Vardeu F, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Bertolino F, Loi A, De Virgiliis S, Cao A. Eur J Pediatr; 1981 Nov 30; 137(3):267-71. PubMed ID: 7318837 [Abstract] [Full Text] [Related]
36. Iron chelation therapy with deferoxamine in Cooley anemia. Cohen A, Schwartz E. J Pediatr; 1978 Apr 30; 92(4):643-7. PubMed ID: 633031 [Abstract] [Full Text] [Related]
37. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Hemoglobin; 2006 Apr 30; 30(2):219-27. PubMed ID: 16798647 [Abstract] [Full Text] [Related]
38. Bone metabolism in thalassemia. Garofalo F, Piga A, Lala R, Chiabotto S, Di Stefano M, Isaia GC. Ann N Y Acad Sci; 1998 Jun 30; 850():475-8. PubMed ID: 9668589 [No Abstract] [Full Text] [Related]
39. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously]. Ferrara M, Galdo Capotorti M, Ponte G, Esposito L. Pediatria (Napoli); 1983 Jun 30; 91(4):371-7. PubMed ID: 6545400 [No Abstract] [Full Text] [Related]
40. Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous infusions of desferrioxamine. Schettini F, Mautone A, Cavallo L, Altomare M, Montagna O, Dell'Edera L. Acta Haematol; 1981 Jun 30; 66(2):96-101. PubMed ID: 6794319 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]